Abstract
Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have